Details for Patent: 10,272,064

Which drugs does patent 10,272,064 protect, and when does it expire?

Patent 10,272,064 protects FUROSCIX and is included in one NDA.

This patent has twenty-four patent family members in fifteen countries.

Summary for Patent: 10,272,064

Title:	Pharmaceutical formulations for subcutaneous administration of furosemide
Abstract:	The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.
Inventor(s):	Michaels Scott A., Muntendam Pieter, Larsen Glenn R.
Assignee:	scPharmaceuticals Inc.
Application Number:	US15877865
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,272,064

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Scpharmaceuticals	FUROSCIX	furosemide	SOLUTION;SUBCUTANEOUS	209988-001	Oct 7, 2022		RX	Yes	Yes			Y

International Family Members for US Patent 10,272,064

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014248164
Brazil	112015025204
Canada	2908935
China	105431145